Abstract Number: 2381 • ACR Convergence 2024
Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database
Background/Purpose: Lupus nephritis (LN) is a complication of systemic lupus erythematosus (SLE) that occurs in 50 percent of patients. LN serves as an important predictor…Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…Abstract Number: 2417 • ACR Convergence 2024
Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with complex multi-systemic involvement. Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus…Abstract Number: 2434 • ACR Convergence 2024
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
Background/Purpose: ESK-001 is a potent, highly selective, oral, allosteric small molecule inhibitor of TYK2 currently being investigated in adults with active SLE in the LUMUS…Abstract Number: 2580 • ACR Convergence 2024
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Background/Purpose: Ianalumab (VAY736) is an afucosylated, fully human IgG1 monoclonal antibody with a dual mechanism of action of enhanced B-cell depletion through antibody-dependent cellular cytotoxicity…Abstract Number: 2677 • ACR Convergence 2024
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…Abstract Number: 0119 • ACR Convergence 2024
Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis
Background/Purpose: Antiphospholipid syndrome (APS) is closely linked with Systemic Lupus erythematosus (SLE) and can influence patient outcomes. The interplay between APS and SLE, including the evolution…Abstract Number: 0182 • ACR Convergence 2024
Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune condition that disproportionally affects individuals from racial and ethnic minority groups with more than 95%…Abstract Number: 0217 • ACR Convergence 2024
Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…Abstract Number: 0611 • ACR Convergence 2024
Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 181
- Next Page »